



MariMed Secures New Funding from Long-Term Capital Partner

Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions

\$46 Million Dollar Financing Facility to Accelerate Company Growth Strategy

NORWOOD, Mass., March 2, 2021 /CNW/ - MariMed, Inc. (OTCQX: MRMD) (the "Company" or "MariMed"), a leading multi-state cannabis operator focused on health and wellness, today announced the closing of a \$46 million financing facility with Hadron Healthcare Fund ("Hadron") pursuant to the terms of a Securities Purchase Agreement ("SPA"). Today's initial funding of \$23 million, will be used to repay substantially all of the Company's long-term debt other than mortgage-backed loans as well as to upgrade and expand MariMed's owned and managed cannabis facilities. The balance of the committed funds will be available for MariMed to continue executing on its strategic plan and complete the consolidation of other state cannabis businesses into MariMed.

"We are thrilled to have been selected by Hadron as their preferred partner to complete this strategic investment in the US MSO sector," said Bob Fireman, CEO of MariMed. "This financing is a substantial recognition of both the Company's position in the industry as well as the strength and track record of our management team. This infusion of capital comes at a key inflection point for MariMed and will not only further strengthen our balance sheet, but also enable us to complete targeted acquisitions and strongly position us to act on other attractive opportunities for accelerated growth as the cannabis industry continues to evolve."

MariMed intends to utilize this capital investment to position itself as one of the leading vertically integrated US multi-state cannabis operators. The Company expects to expand its cultivation capacity to increase cannabis production and implement automated technologies and specialized equipment to improve the efficiencies in the Company's production labs and kitchens in order to produce greater volumes of MariMed's portfolio of proprietary brands and infused products. MariMed's executive leadership team has significant experience and an extensive track record of executing in the cannabis industry. To date, the MariMed team has successfully won 17 cannabis licenses in multiple states for itself and on behalf of its clients and has developed over 300,000 square feet of state-of-the-art, regulatory compliant cultivation, production and dispensing facilities.

"When we looked at the history of the MariMed and its management team, we strongly felt MariMed was the best opportunity for our continued interest and investment into the United States MSO space," said Marco D'Attanasio, CIO of Hadron Capital (Cayman) Ltd, the investment manager of Hadron Healthcare Fund. "MariMed's strong brand presence, operational excellence, and management track record, supported by our capital investment, will give them the best tools to continue to execute and drive stockholder value. We view MariMed assets and revenue as a platform to build a top professional and profitable MSO in the cannabis industry. We look forward to working with them as a long-term partner."

Transaction Details

The SPA provides for the sale of up to \$46 million of Series C Convertible Preferred Shares of the Company. At today's initial closing, Hadron purchased \$23 million of Units for \$3.70 per Unit. Each Unit consists of one share of Series C Preferred Stock and a Common Stock purchase warrant. Each share of Series C Preferred Stock is convertible, at Hadron's option, into five shares of Common Stock and each warrant is exercisable, at an exercise price of \$1.087 per share, for one-half of a share of Common Stock for each conversion share (2 ½ warrants shares per Unit). The balance of the committed funds (up to \$23 million) will be issued on the same terms as the securities issued today and will be available for MariMed to complete the consolidation of other state cannabis businesses units into MariMed. In addition, if Hadron exercises all of the warrants for cash, MariMed will receive additional proceeds of approximately \$34 million. Beacon Securities Limited introduced the parties to the transaction.

About Hadron Capital (Cayman) Ltd

Hadron Capital (Cayman) Ltd is an independent investment manager with global reach that was founded in 2004. Hadron has a track record of strong returns and has won multiple performance awards over the years. Hadron was an early investor in some of the largest multi-state operators in the sector and its US cannabis investment portfolio is valued at over US \$300 million. Hadron's investment philosophy is strongly based on bottom-up, thorough and deep analysis. Hadron works with companies to unleash value and acts as a long-term financial partner and provider of capital for their portfolio companies.

About MariMed

MariMed Inc., a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units, keeping it at the forefront of cannabis science and innovation. Proprietary formulations created by the Company's technicians are embedded in its industry-leading products and brands, including Betty's Eddies™, Nature's Heritage™, Bourne Baking Co., and Kalm Fusion™. For additional information, visit marimedinc.com.

Important Caution Regarding Forward-Looking Statements:

This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.'s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events, including estimates and projections about its business based on certain assumptions of its management, including those described in this release. These statements are not guaranteeing of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement, and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned," "estimated," "preparing," "potential," "expected," "looks" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

All trademarks and service marks are the property of their respective owners.

SOURCE MariMed Inc.

Vendor Data

Key	Value
Resource ID	202103021605CANADANWCANADAPR_C6012
AMX:Alert	FALSE
AMX:Company Record	OTC-PINK[MRMD]CUSIP:56782V107;ISIN:US56782V1070[MariMed Inc][source DUNS:969022057;NECOID:8400769;ACORN:5011400769]SIGNIFICANT PINX REFERENCE
AMX:Headline Only	FALSE
AMX:Publish Reason	ORIGINAL
AMX:ReadKey	8a8efa8ffab7d2797ba82c65f28bd2029c0cfda0cebbfd6c14183674365e362a9b4ef7133cc02d99134e27d1b08bb0cd5777738da17ceae48091346e5af425f
AMX:ReadKey	8a8efa8ffab7d2797ba82c65f28bd2029c0cfda0cebbfd6c14183674365e362a9b4ef7133cc02d99134e27d1b08bb0cd5777738da17ceae48091346e5af425f
AMX:Source Ticker	OTC-PINK:MRMD
AMX:Source Ticker	OTC-QX:MRMD
AMX:Special Code	PC/iwc.1092
AMX:Special Code	PC/metabot.dr-feedbot2
AMX:Special Code	PC/metabot.nj3plwisfeedpd2
AMX:Special Code	PS/p.CANADANW
AMX:Special Code	PS/s.CANADAPR
AMX:Special Code	PT/MTYPE
AMX:Special Code	PT/MTYPE.Text
AMX:Special Code	PT/RIGHTS
AMX:Special Code	PT/RIGHTS.CLEARED
AMX:Special Code	PT/TOP
AMX:Special Code	PT/TYPE
AMX:Special Code	PT/TYPE.PR
AMX:Special Code	TT/TOPIC#9#75#99
AMX:Special Code	TT/business#8#50#85
AMX:Story Lead	Capital Infusion to Strengthen Balance Sheet and Provide Funding for Strategic Acquisitions \$46 Million Dollar Financing Facility to Accelerate Company Growth Strategy NORWOOD, Mass., March 2, 2021 /CNW/ - MariMed, Inc. (OTCQX: MRMD) (the "Company" or "MariMed"), a leading multi-state cannabis operator focused on health and wellness, today announced the closing of a \$46 million financing ...
AMX:Temporary	FALSE
ANPA:Category	f
ANPA:Priority	r
CANADANW:APT Routing
CANADANW:AttentionLine	co.594102
CANADANW:Billing Code	corcus
CANADANW:CNum	C6012
CANADANW:CO Field	MariMed Inc.
CANADANW:ClientRefId	852547
CANADANW:CnwSocialToolsEnabled	N
CANADANW:CnwXMLNewsVersion	1.4
CANADANW:Company Code	OTC-QX:MRMD
CANADANW:CompanyRefId	594102
CANADANW:Contact	Company Contact - MRMD, Jon Levine, CFO, MariMed Inc.; Investor Relations: Rob Kelly, Mattio Communications, ir@mattio.com; Media Relations: Patrick Martin, Mattio Communications, marimed@mattio.com
CANADANW:Creator	MATTIO Communications
CANADANW:Crossing Date	20210302
CANADANW:Crossing DateTime	202103021605
CANADANW:Crossing Time	1605
CANADANW:Css	/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } .prntac{ TEXT-ALIGN: CENTER } text/css
CANADANW:CssType	
CANADANW:Data Features Routing	xxxxx
CANADANW:DatabaseLine	ME
CANADANW:Dateline Date	March 2, 2021
CANADANW:Dateline Distributor	CNW
CANADANW:Dateline Location	NORWOOD, Mass.
CANADANW:Deliver As	202103021605CANADANWCANADAPR3084129-1-1
CANADANW:Editor Initials	PR
CANADANW:First Created	2021-03-02T16:05:00-05:00
CANADANW:Format	HybridRelease
CANADANW:Format	WideRelease
CANADANW:From Echo	TRUE
CANADANW:From Uses	TRUE
CANADANW:Geographic Code	RE/Massachusetts
CANADANW:Geographic Code Name	Massachusetts
CANADANW:Industry Code	IN/OTC
CANADANW:Industry Code	IN/THC
CANADANW:IrisParentID	3296459
CANADANW:Jim-Dash Line	03/02/2021
CANADANW:OtherInformation	CnwUrl http://www.newswire.ca/en/releases/archive/March2021/02/c6012.html
CANADANW:PT Data	CoLineSource MariMed Inc.
CANADANW:PT Data	DestinationCode CNW ReleaseWatch English
CANADANW:PT Data	DestinationCode corcus
CANADANW:PT Data	PointToPointResend false
CANADANW:PT Data	ProductCode corcus
CANADANW:PT Data	ShowInMediaRooms true
CANADANW:PT Data	StoryID 3296459
CANADANW:PT Data	VR_AcctNum 852547
CANADANW:PT Data	VR_ReleaseType Standard
CANADANW:PT Data	cnwwebmax N
CANADANW:PT Data	prnewswire.com N
CANADANW:PT Data	prnj N
CANADANW:Primary Company Code	OTC-QX:MRMD
CANADANW:RefHTML	View original content: http://www.newswire.ca/en/releases/archive/March2021/02/c6012.html

Key	Value
CANADANW:Slug	MariMed-NewFunding
CANADANW:Source	MariMed Inc.
CANADANW:Source Bureau	TO
CANADANW:Special Code	PC/1stAcc_5011380
CANADANW:Special Code	PC/Billing_corcus
CANADANW:Special Code	PC/bureau_TO
CANADANW:Special Code	PC/category.f
CANADANW:Special Code	PC/cl.852547
CANADANW:Special Code	PC/co.594102
CANADANW:Special Code	PC/contact
CANADANW:Special Code	PC/id_C6012
CANADANW:Special Code	PC/port_91
CANADANW:Special Code	PC/priority.r
CANADANW:Special Code	PC/t.210302160502226
CANADANW:Special Code	PC/t.210302160502706
CANADANW:Special Code	PC/ticker
CANADANW:Special Code	PT/lang.en
CANADANW:Subject Code	SU/MAT
CANADANW:WAVO Routing
CANADANW:WorkOrderNum	202103023296459
NEWSEdge:AmxSource	Canada_Newswire
NEWSEdge:Special Code	PS/Canada_Newswire
NEWSEdge:Special Code	PS/Canada_Newswire
NEWSEdge:Special Code	PS/src.365.2
WAVO:Publish Reason	ORIGINAL
WAVO:alert	FALSE
WAVO:headline_only	FALSE
WAVO:temporary	FALSE